These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36129561)

  • 1. Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia.
    Albuloushi A; Rhoten M; Kelly J; Sylvester KW; Grandoni J; Connors JM
    J Thromb Thrombolysis; 2022 Nov; 54(4):597-604. PubMed ID: 36129561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia.
    Cirbus K; Simone P; Austin Szwak J
    J Clin Pharm Ther; 2022 Jan; 47(1):112-118. PubMed ID: 34704283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia.
    Davis KA; Davis DO
    Eur J Haematol; 2017 Oct; 99(4):332-335. PubMed ID: 28672052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.
    Warkentin TE; Pai M; Linkins LA
    Blood; 2017 Aug; 130(9):1104-1113. PubMed ID: 28646118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia.
    Davis K; Sebaaly J; Wooten L; Khouli C; Mihm A; Nisly SA
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):417-424. PubMed ID: 35040095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia.
    Barlow A; Barlow B; Reinaker T; Harris J
    Pharmacotherapy; 2019 Aug; 39(8):837-853. PubMed ID: 31233222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-Induced Thrombocytopenia (HIT) in the Direct Oral Anticoagulants (DOAC) Era.
    Mahoney RC; DeLoughery TG; Jung E; Shalhub S; Liem TK
    Ann Vasc Surg; 2024 Nov; 108():166-170. PubMed ID: 38942369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review.
    Sadowski C; Reinert JP
    Am J Health Syst Pharm; 2024 Sep; 81(19):e584-e593. PubMed ID: 38651828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment.
    Hvas AM; Favaloro EJ; Hellfritzsch M
    Expert Rev Hematol; 2021 Apr; 14(4):335-346. PubMed ID: 33736552
    [No Abstract]   [Full Text] [Related]  

  • 10. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study.
    Linkins LA; Warkentin TE; Pai M; Shivakumar S; Manji RA; Wells PS; Wu C; Nazi I; Crowther MA
    J Thromb Haemost; 2016 Jun; 14(6):1206-10. PubMed ID: 27061271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series.
    Carré J; Guérineau H; Le Beller C; Mauge L; Huynh B; Nili R; Planquette B; Clauser S; Smadja DM; Helley D; Lillo-Le Louet A; Gendron N; Calmette L
    Front Med (Lausanne); 2021; 8():713649. PubMed ID: 34422867
    [No Abstract]   [Full Text] [Related]  

  • 12. Direct-acting oral anticoagulants as emerging treatment options for heparin-induced thrombocytopenia.
    Miyares MA; Davis KA
    Ann Pharmacother; 2015 Jun; 49(6):735-9. PubMed ID: 25855702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.
    Tran PN; Tran MH
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):201-209. PubMed ID: 28301915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation prescribing patterns in patients with cancer.
    Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
    J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of anticoagulation selection for acute venous thromboembolism.
    Badreldin H; Nichols H; Rimsans J; Carter D
    J Thromb Thrombolysis; 2017 Jan; 43(1):74-78. PubMed ID: 27592341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia.
    Farasatinasab M; Zarei B; Moghtadaei M; Nasiripour S; Ansarinejad N; Zarei M
    J Clin Pharmacol; 2020 Oct; 60(10):1362-1366. PubMed ID: 32519800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin induced thrombocytopenia. Contemporary therapeutic approaches in light of the new oral anticoagulants.
    Sanidas EA; Viniou NA; Diamantopoulos P; Barbetseas J
    Hamostaseologie; 2015; 35(4):372-5. PubMed ID: 26302031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heparin-induced thrombocytopenia. New therapeutical options].
    Seculini Patiño CE; Tabares AH
    Medicina (B Aires); 2016; 76(4):230-4. PubMed ID: 27576282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective evaluation of direct oral anticoagulant (DOAC) management strategies in patients with cancer on active chemotherapy.
    Tran E; Ledbetter LE
    J Thromb Thrombolysis; 2023 May; 55(4):721-728. PubMed ID: 36781620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review.
    Dhakal P; Pathak R; Giri S; Murthy GS; Bhatt VR
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):87-91. PubMed ID: 26695419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.